Superhuman Inc. v. ThermoLife International LLC: Voluntary Dismissal With Prejudice
Superhuman Inc. filed a patent infringement suit against ThermoLife International LLC in the Central District of California, asserting US8455531B2 over Superhuman Extreme and Superhuman Pre supplement products. The case was voluntarily dismissed with prejudice just 41 days after filing — before ThermoLife served any responsive pleading.
A 41-day infringement action ends before ThermoLife could respond
On November 5, 2024, Superhuman Inc. filed suit against ThermoLife International LLC in the U.S. District Court for the Central District of California (Case No. 2:24-cv-09589), asserting infringement of US8455531B2 — a patent covering pre-workout supplement formulations. The accused products were ThermoLife’s Superhuman Extreme and Superhuman Pre supplements, placing two competing brands squarely in conflict over branded product names and underlying formulation IP.
Just 41 days after filing, on December 16, 2024, Superhuman Inc. voluntarily dismissed the action with prejudice pursuant to Federal Rule of Civil Procedure 41(a)(1)(A)(i). The dismissal was filed before ThermoLife had served any responsive pleading or motion for summary judgment. A with-prejudice dismissal under Rule 41(a)(1)(A)(i) is self-executing and does not require a court order, but its with-prejudice character is legally significant: Superhuman Inc. is permanently barred from re-asserting the same claims against ThermoLife on the same patent.
The 41-day lifecycle — shorter than virtually any contested patent matter — suggests the parties may have reached a private resolution, or that Superhuman Inc. reassessed the viability of its claims once litigation counsel engaged. The public record does not disclose settlement terms, licensing arrangements, or any court-ordered relief. The with-prejudice election, rather than a without-prejudice exit, is notable: it typically signals either a negotiated resolution with a no-refile commitment, or a strategic decision to permanently foreclose the litigation path.
Filing to Voluntary dismissal in 41 days
41 days — resolved before defendant filed any responsive pleading, well under median district court lifecycle
Dismissed with prejudice: what Rule 41(a)(1)(A)(i) means for both parties
Rule 41(a)(1)(A)(i): self-executing, no court order needed
Under FRCP 41(a)(1)(A)(i), a plaintiff may dismiss an action without a court order if filed before the defendant serves a responsive pleading or summary judgment motion. The dismissal is effective upon filing the notice. Here, Superhuman Inc. elected to dismiss with prejudice — an unusual choice under this rule, as the default is without prejudice — indicating a deliberate and permanent relinquishment of these claims.
Plaintiff-initiated, pre-answerWith prejudice: Superhuman cannot refile these claims against ThermoLife
A dismissal with prejudice operates as a final adjudication on the merits, permanently barring Superhuman Inc. from reasserting the same patent claims against ThermoLife on US8455531B2. A without-prejudice dismissal would have preserved the option to refile. The public record does not disclose why the with-prejudice election was made — it may reflect a settlement with a no-refile covenant, or a unilateral strategic concession by plaintiff.
Claims permanently extinguishedThermoLife exits without ever filing a response
ThermoLife International LLC was never required to file an answer, counterclaim, or invalidity defence. The with-prejudice dismissal provides ThermoLife with permanent protection against Superhuman Inc. reasserting these specific claims. However, ThermoLife retains no affirmative declaratory judgment or invalidity ruling — the patent US8455531B2 remains valid and potentially enforceable against other parties.
No merits ruling; patent survivesUS8455531B2 remains live — third-party exposure persists
Because the case ended without any invalidity finding or claim construction ruling, US8455531B2 emerges intact and fully enforceable. Other supplement brands operating in the pre-workout formulation space cannot rely on this case as precedent for invalidity or non-infringement. Companies with competing products should treat this patent as an active enforcement risk and consider independent freedom-to-operate analysis.
Patent remains enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Superhuman Inc. | Company | Pre-workout supplement brand — holder of US8455531B2 covering supplement formulationsSearch in Eureka ↗ |
| Defendant | ThermoLife International LLC | Company | ThermoLife International LLC — sports nutrition ingredient and supplement companySearch in Eureka ↗ |
| Plaintiff counsel | A. Colin Wexler | Attorney | Counsel for Superhuman Inc.Search in Eureka ↗ |
| Plaintiff counsel | Lawrence M. Hadley | Attorney | Counsel for Superhuman Inc.Search in Eureka ↗ |
| Plaintiff counsel | Paul J Sauerteig | Attorney | Counsel for Superhuman Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert D Leighton | Attorney | Counsel for Superhuman Inc.Search in Eureka ↗ |
| Plaintiff law firm | Glaser Weil Fink Howard Jordan and Shapiro LLP | Law Firm | Representing Superhuman Inc.Search in Eureka ↗ |
| Plaintiff law firm | Goldberg Kohn Ltd | Law Firm | Representing Superhuman Inc.Search in Eureka ↗ |
| Defendant counsel | Alex H. Chan | Attorney | Counsel for ThermoLife International LLCSearch in Eureka ↗ |
| Defendant counsel | Gregory K. Sobolski | Attorney | Counsel for ThermoLife International LLCSearch in Eureka ↗ |
| Defendant counsel | Timothy Devlin | Attorney | Counsel for ThermoLife International LLCSearch in Eureka ↗ |
| Defendant law firm | Devlin Law Firm LLC | Law Firm | Representing ThermoLife International LLCSearch in Eureka ↗ |
| Defendant law firm | Latham & Watkins LLP | Law Firm | Representing ThermoLife International LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | California Central District CourtSearch in Eureka ↗ |
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and explicitly states it is made with prejudice, before ThermoLife served any responsive pleading. The with-prejudice designation is legally operative without court approval under this rule and functions as a final judgment on the merits for res judicata purposes. Notably, the notice contains no reference to settlement, licensing, or agreed terms — leaving the commercial rationale entirely within the private record. ThermoLife gains permanent protection from these specific claims; Superhuman Inc. retains ownership of US8455531B2 for use against other parties.
US8455531B2 — Pre-workout supplement formulation patent
US8455531B2 (application number US13/038537) covers formulations in the pre-workout and sports nutrition supplement space. The patent was asserted in the context of Superhuman Extreme and Superhuman Pre products, suggesting the claims relate to specific ingredient combinations, dosing ratios, or compositional features characteristic of pre-workout supplements. The application number series is consistent with filings in the early 2010s, a period of significant formulation patent activity in the sports nutrition sector.
For the sports nutrition and supplement industry, formulation patents like US8455531B2 represent a meaningful competitive moat — protecting specific ingredient combinations from direct replication by competing brands. The fact that Superhuman Inc. was willing to assert this patent in federal court, and then dismiss with prejudice before any defence was filed, suggests the patent holder views the claims as commercially significant but may have secured its objectives through a non-public resolution. Competing brands in the pre-workout segment should treat this patent as an active enforcement risk.
Should you run an FTO analysis against US8455531B2?
Any company formulating or marketing pre-workout supplements — particularly products bearing performance-enhancing ingredient blends similar to those in Superhuman Extreme or Superhuman Pre — should assess exposure to US8455531B2. The case’s with-prejudice dismissal provides no invalidity shield. The patent remains in force, and this litigation confirms the holder is willing to assert it. R&D teams reformulating existing products or launching new pre-workout SKUs face the highest near-term exposure.
PatSnap Eureka’s FTO Search Agent enables rapid claim mapping against US8455531B2, surfacing relevant prior art, identifying claims most likely to read on your product formulation, and benchmarking against the full citation landscape for this patent family. Eureka can also monitor for continuation applications and downstream enforcement activity, giving your product and legal teams a live view of the risk profile before a new SKU launches.
Run a freedom-to-operate analysis on US8455531B2 to assess your product’s exposure
Run FTO in Eureka →Similar patent infringement cases in sports nutrition and supplement formulations
Explore related patent infringement actions involving supplement formulation IP filed in California federal courts, including pre-workout and performance nutrition disputes.
What this case signals for the sports nutrition IP landscape
A rapid with-prejudice exit before any response is filed is rarely accidental. It warrants close reading by supplement sector IP teams.
With-prejudice dismissal signals a negotiated exit, not a simple withdrawal
Plaintiffs who simply lose confidence in a case typically dismiss without prejudice to preserve optionality. Electing with-prejudice under Rule 41(a)(1)(A)(i) — before any court pressure — strongly suggests either a private settlement with a no-refile clause or a deliberate strategic concession. IP teams in the supplement sector should monitor for downstream licensing activity involving US8455531B2.
US8455531B2 is unscathed: no invalidity finding, no claim construction
This case produced zero patent law precedent. No court reviewed the claims, construed terms, or addressed validity. For competitors in the pre-workout formulation space, this means the patent retains its full offensive potential. Any company with a product that could read on the claims of US8455531B2 should conduct a fresh FTO review — this litigation provides no safe-harbour arguments.
Superhuman v ThermoLife — key questions answered
Superhuman Inc. filed a patent infringement action against ThermoLife International LLC in the Central District of California on November 5, 2024, asserting US8455531B2 over the Superhuman Extreme and Superhuman Pre supplement products. On December 16, 2024 — 41 days after filing and before ThermoLife filed any responsive pleading — Superhuman Inc. voluntarily dismissed the case with prejudice under FRCP 41(a)(1)(A)(i).
A dismissal with prejudice under Rule 41(a)(1)(A)(i) permanently bars Superhuman Inc. from refiling the same claims against ThermoLife based on US8455531B2. It operates as a final adjudication on the merits for res judicata purposes. Unlike a without-prejudice dismissal, Superhuman cannot reassert these specific claims against ThermoLife in a future action.
Yes. Because the case was dismissed before any court ruling on validity, claim construction, or infringement, US8455531B2 remains fully valid and enforceable. No invalidity finding was made, and no claim construction ruling was issued. The patent can still be asserted against other parties in the supplement formulation space. Competitors cannot rely on this case as a precedent for non-infringement or invalidity.
The most common explanations include: (1) a negotiated settlement in which the with-prejudice dismissal serves as the plaintiff’s consideration — often paired with a no-refile covenant; (2) a unilateral strategic decision by plaintiff that the claims are unlikely to succeed; or (3) a commercial resolution addressing broader business concerns beyond the litigation. The public record in this case is silent on the specific reason, so no definitive explanation can be confirmed.
The accused products were ThermoLife International LLC’s Superhuman Extreme supplements and Superhuman Pre supplements — both pre-workout formulation products. The case was filed in the Central District of California, and the infringement action was the sole stated cause of action. No product-specific claim construction or infringement analysis was published before the case was dismissed.
PatSnap Eureka searches patents and litigation data to answer instantly.